United States Diabetes Drugs Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

United States Diabetes Drugs Market Overview

Diabetes drugs include a wide spectrum of therapeutic agents developed to control blood glucose levels and prevent diabetes-related complications. These medications act through diverse mechanisms, including enhancing insulin secretion, improving insulin sensitivity, and reducing glucose absorption. The diabetes drugs market in United States is expanding due to rising diabetes incidence, sedentary lifestyles, and a growing aging population. Moreover, strong investments in research, favorable reimbursement policies, and advancements in biologics and biosimilars are fueling market growth. The market was valued at USD 14.70 Billion in 2025, highlighting sustained demand and innovation in diabetes management. The increasing focus on patient-centric care, early diagnosis, and the adoption of innovative formulations such as oral glucagon-like peptide-1 (GLP-1) receptor agonists are shaping the therapeutic landscape.

United States Diabetes Drugs Market Growth Driver

Expanding Access to Affordable Therapies Accelerating the Market Demand

The rising focus on improving patient access to affordable and effective treatment options for type II diabetes is a significant factor driving the growth in the market. Supporting this trend, in December 2024, the U.S. Food and Drug Administration approved the first generic of once daily liraglutide injection, referencing Victoza, developed by Hikma Pharmaceuticals USA Inc. This approval marks a significant step toward reducing treatment costs and addressing ongoing shortages of GLP-1 receptor agonists. Such initiatives are expected to enhance medication accessibility, driving consistent market growth across the nation.

United States Diabetes Drugs Market Trends

Key trends in the market include the increasing adoption of interchangeable biosimilar insulins and the growing use of generic GLP-1 therapies.

Rising Adoption of Interchangeable Biosimilar Insulins is Likely to Propel the Market in the United States

The increasing adoption of interchangeable biosimilar insulins, enhancing affordability and patient access, is a growing trend shaping the market growth. In July 2025, Biocon Biologics Ltd. received U.S. FDA approval for Kirsty™ (Insulin Aspart-xjhz), the first and only interchangeable rapid-acting biosimilar insulin aspart. This milestone strengthens Biocon’s leadership in biosimilar insulin therapy and expands treatment options for diabetes patients. Such approvals are expected to accelerate innovation, competition, and affordability, significantly boosting the market’s overall growth trajectory.

Growing Adoption of Generic GLP-1 Therapies is Boosting the Market Value

The market is witnessing a significant shift with the rising adoption of generic GLP-1 receptor agonists, improving affordability and accessibility for patients with type 2 diabetes. In June 2024, Teva Pharmaceuticals, Inc. launched the authorized generic of Victoza® (liraglutide injection 1.8mg), marking the first-ever generic GLP-1 product in the U.S. market. This development underscores growing competition and innovation in diabetes management solutions, ultimately enhancing treatment availability and driving the overall growth of the diabetes drugs market in the United States.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

United States Diabetes Drugs Market Share

Type II Expected to Lead the Market Share by Diabetes Type

The market is segmented by diabetes type into Type I and Type II. Among these, Type II diabetes is projected to lead the market during the forecast period, driven by its significantly higher prevalence and the increasing adoption of advanced therapeutic options such as GLP-1 receptor agonists and SGLT2 inhibitors. The rising incidence among adults, along with growing cases among younger populations, further contributes to market expansion. The Centers for Disease Control and Prevention (CDC) reported that over 38 million Americans have diabetes, with 90% to 95% suffering from Type II diabetes, emphasizing its substantial dominance. Continuous drug innovation and lifestyle awareness programs are anticipated to reinforce the segment’s market leadership in the coming years.

Leading Players in the United States Diabetes Drugs Market

Other key players in the market include Sanofi, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Dexcom, Inc., and F. Hoffmann La Roche.

United States Diabetes Drugs Market Segmentation

Key Questions Answered in the United States Diabetes Drugs Market Report

• What was the United States diabetes drugs market value in 2025?
• What is the United States diabetes drugs market forecast outlook for 2026-2035?
• What are the major factors aiding the United States diabetes drugs market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major United States Diabetes Drugs market trends?
• Which drugs is expected to dominate the market segment?
• Which diabetes type is projected to lead the market segment?
• Which distribution channel is anticipated to drive the market segment?
• Which end user is expected to drive the market segment?
• Who are the key players involved in the United States diabetes drugs market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?